Einhorn L H, Williams S D, Stevens E E, Bond W H, Chenoweth L
Cancer. 1983 Apr 15;51(8):1348-52. doi: 10.1002/1097-0142(19830415)51:8<1348::aid-cncr2820510804>3.0.co;2-7.
Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV disease and 11 had systemic symptoms. Although hematologic toxicity was considerable, there was no drug related mortality. Eight patients achieved a complete remission (CR), and five are currently in a continuous CR of five, 24, 30, 34, and 36 months duration, respectively. An additional patient had a 30-month CR and relapsed with localized lymphadenopathy and is currently disease-free following involved-field radiotherapy 46 months from initiation of VABCD. This study suggests that long-term disease-free survival and potential cure can be achieved with VABCD in MOPP-refractory Hodgkin's disease.
18例晚期霍奇金病患者，对氮芥、长春新碱、泼尼松和丙卡巴肼联合化疗（MOPP）耐药，接受了长春碱、阿霉素（阿霉素）、博来霉素、环己亚硝脲和达卡巴嗪（DTIC）（VABCD）治疗。15例患者为IV期疾病，11例有全身症状。尽管血液学毒性相当大，但无药物相关死亡。8例患者实现完全缓解（CR），5例目前分别处于持续5个月、24个月、30个月、34个月和36个月的CR状态。另有1例患者有30个月的CR，后因局部淋巴结病复发，自VABCD开始46个月后接受受累野放疗，目前无病。本研究表明，VABCD可使MOPP耐药的霍奇金病实现长期无病生存并有可能治愈。
